Overweight Clinical Trial
Official title:
The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults
Verified date | March 2023 |
Source | TCI Co., Ltd. |
Contact | HUANG YU-JYUN |
Phone | 0934173838 |
nneder34[@]gmail.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To assess whether orange peel fermentation has the effect of reducing body fat in adults
Status | Recruiting |
Enrollment | 124 |
Est. completion date | December 31, 2023 |
Est. primary completion date | October 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Adults between the ages of 20 and 65 who are willing to sign the consent form of the subject. 2. For those with BMI = 24 or fatty liver, male body fat = 25%, female body fat = 30%. 3. Those who are not pregnant and are willing to cooperate with contraception during the trial period. 4. No history of cardiovascular disease, history of organ transplantation, history of epilepsy or convulsions, liver and kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history). Exclusion Criteria: 1. Pregnant women, people with a history of cardiovascular disease, organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history). 2. No person who has received major surgery or bariatric surgery (according to medical history). 3. I have used drugs that affect body fat, waist circumference or significantly increase weight, such as systemic corticosteroids, tricyclic antidepressants, atypical psychiatric drugs, and mood stability in the current or 3 months before participating in the screening Drugs (according to medical history). |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
TCI Co., Ltd. |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change of body fat mass | The body fat mass (kg) was assessed by InBody770 | Weeks 0, 4 and 8 | |
Primary | The change of Triglyceride | Venous blood was sampled to measure concentrations of Triglyceride | Weeks 0, 4 and 8 | |
Primary | The change of Total cholestrol | Venous blood was sampled to measure concentrations of Total cholestrol | Weeks 0, 4 and 8 | |
Primary | The change of HDL-cholestrol | Venous blood was sampled to measure concentrations of HDL-cholestrol | Weeks 0, 4 and 8 | |
Primary | The change of LDL-cholestrol | Venous blood was sampled to measure concentrations of LDL-cholestrol | Weeks 0, 4 and 8 | |
Primary | The change of body mass index (BMI) | BMI is a measurement of a person's leanness or corpulence based on their height and weight, and is intended to quantify tissue mass.The body mass index (BMI, kg/m^2) and body mass (kg) were assessed by InBody770. | Weeks 0, 4 and 8 | |
Primary | The change of body fat percentage | The body fat percentage (%) was assessed by InBody770. | Weeks 0, 4 and 8 | |
Primary | The change of visceral fat | The visceral fat (10 cm^2) was assessed by InBody770. | Weeks 0, 4 and 8 | |
Primary | The change of fasting glycemia | Venous blood was sampled to measure concentrations of fasting glycemia | Weeks 0, 4 and 8 | |
Primary | The change of aspartate aminotransferase | Venous blood was sampled to measure concentrations of aspartate aminotransferase | Weeks 0, 4 and 8 | |
Primary | The change of alanine aminotransferase | Venous blood was sampled to measure concentrations of alanine aminotransferase | Weeks 0, 4 and 8 | |
Primary | The change of albumin | Venous blood was sampled to measure concentrations of creatine | Weeks 0, 4 and 8 | |
Primary | The change of creatine | Venous blood was sampled to measure concentrations of creatine | Weeks 0, 4 and 8 | |
Primary | The change of uric acid | Venous blood was sampled to measure concentrations of uric acid | Weeks 0, 4 and 8 | |
Primary | The change of white blood cell | Venous blood was sampled to measure concentrations of white blood cell | Weeks 0, 4 and 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
Completed |
NCT02829229 -
Community-based Obesity Treatment in African American Women After Childbirth
|
N/A | |
Completed |
NCT03097237 -
High Fiber Rye Foods for Weight and Body Fat Reduction
|
N/A |